Trump slashes Medicare drug subsidies, cutting against affordability message

The end of a subsidy program that helped keep costs down for Medicare drug coverage could leave millions of seniors with higher monthly costs, a move that undermines the Trump administration’s message of cutting drug costs.

President Trump often touts his push for access to cheaper drugs through the TrumpRx platform and making “most-favored-nation” deals with drug companies.

But healthcare advocacy and policy organizations have said the end of the subsidy program will raise premium costs and put a burden on seniors at a time when costs are already high.

“President Trump has had a lot of strong rhetoric on drug prices and negotiating deals with manufacturers to lower prices, and they’ve taken a lot of different steps to try to bring drug prices down,” Juliette Cubanski, vice president and director of the Program on Medicare Policy at KFF, told The Hill.

Bold News stores the normalized extraction for evidence and analysis. This public wrapper shows a limited excerpt; use the original link for the publisher's complete presentation.